What Influences Patient Outcome in Obstructive Airway Disease?
This study has been completed.
Sponsor:
University of Dundee
Information provided by:
University of Dundee
ClinicalTrials.gov Identifier:
NCT01221480
First received: October 14, 2010
Last updated: October 19, 2010
Last verified: October 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this observational study is to utilise the established record linkage data available in Tayside to investigate hospital admissions, exacerbations and mortality in COPD.
| Condition |
|---|
|
COPD |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function. |
Further study details as provided by University of Dundee:
Primary Outcome Measures:
- All-cause Mortality
Secondary Outcome Measures:
- Hospital Admissions
- COPD exacerbations
| Enrollment: | 5977 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | October 2010 |
| Groups/Cohorts |
|---|
| Beta Blocker Use |
| No beta blocker use |
Eligibility| Ages Eligible for Study: | 50 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
COPD patients within NHS Tayside, UK
Criteria
Inclusion Criteria:
- Data collected through TARDIS database
Exclusion Criteria:
- History of asthma or malignancy. Less than 50 years of age
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| Responsible Party: | Dr Philip M Short, University of Dundee |
| ClinicalTrials.gov Identifier: | NCT01221480 History of Changes |
| Other Study ID Numbers: | SHO002 |
| Study First Received: | October 14, 2010 |
| Last Updated: | October 19, 2010 |
| Health Authority: | United Kingdom: Tayside Medical Research Ethics Committee |
Additional relevant MeSH terms:
|
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Lung Diseases Respiratory Tract Diseases Adrenergic beta-Antagonists Adrenergic Antagonists |
Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 21, 2013